Booster dose of Pfizer/BioNTech coronavirus vaccine shows 95.6% efficacy in Phase 3 trial, companies say
By Jacqueline Howard, CNN A booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — against…
Continue Reading